Pdl Biopharma Inc (NASDAQ:PDLI) has grabbed attention from the analysts, when it saw a value increase of 0% or 0 points in the last trading session to close at $3.19. A total of 1.06 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 1.67 Million shares, while its relative volume stands at 0.63. Pdl Biopharma Inc (NASDAQ:PDLI) has a market cap of $465.71 Million and the number of outstanding shares have been calculated 145.99 Million.

Shares of Pdl Biopharma Inc (NASDAQ:PDLI) currently have an Average Brokerage Recommendation of 3, number of Recs in ABR is 1 while industry rank of the company by ABR is out of 256. Out of the analyst recommendations 0 rate Pdl Biopharma Inc (NASDAQ:PDLI) stock a Buy, 0 rate the stock Outperform, 1 rate Hold, 0 rate Underperform and 0 recommend a Sell.

Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $3 on the stock, this valuation is based on 1 number of opinions. The most optimistic analyst sees the stock reaching $3 while the most conventional has $3 target price.

Pdl Biopharma Inc (NASDAQ:PDLI) as of recent trade, has shown weekly upbeat performance of 5.63% which was maintained at 6.69% in 1-month period. During the past three months the stock gain 27.6%, bringing six months performance to 24.61%. Yearly performance of the stock shows a bullish trend of 14.34% while year-to-date (YTD) performance reflected 10% positive outlook.

While taking a glance at financials, we can look at a number of key indicators. Pdl Biopharma Inc (NASDAQ:PDLI) has trailing twelve month Return on Assets of -5.9%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of -8% and a Return on Investment of 11.9%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.

While having a peek at profitability ratios Pdl Biopharma Inc (NASDAQ:PDLI) has trailing twelve month gross margin at 75.2%, its trailing twelve month operating margin stands at -22.1% whereas its trailing twelve month net profit margin spots at -28.4%.

However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The company’s forward price to earnings ratio for next fiscal year is 25.73. Pdl Biopharma Inc (NASDAQ:PDLI)’s price to free cash flow for trailing twelve months is 0. Its beta value stands at 0.51.

The company’s quick ratio for most recent quarter is 10.6 along with current ratio for most recent quarter of 10.9. Total debt to equity ratio of the company for most recent quarter is 0.17 whereas long term debt to equity ratio for most recent quarter is 0.17.